Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 177

1.

Role of everolimus in the treatment of advanced neuroendocrine tumor: a meta-analysis of randomized trials.

Zhuo ZG, Zhu YK, Deng HY, Li G, Luo J, Alai GH, Lin YD.

J BUON. 2019 Jan-Feb;24(1):368-373.

2.

Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study.

Yao JC, Oh DY, Qian J, Park YS, Herbst F, Ridolfi A, Izquierdo M, Ito T, Jia L, Komoto I, Sriuranpong V, Shimada Y.

Onco Targets Ther. 2019 Feb 28;12:1717-1728. doi: 10.2147/OTT.S182259. eCollection 2019.

3.

Observational Study to Assess Quality of Life in Patients with Pancreatic Neuroendocrine Tumors Receiving Treatment with Everolimus: The OBLIQUE Study (UK Phase IV Trial).

Ramage JK, Punia P, Faluyi O, Frilling A, Meyer T, Saharan R, Valle JW.

Neuroendocrinology. 2019;108(4):317-327. doi: 10.1159/000497330. Epub 2019 Jan 30.

4.

Efficacy and Safety of Everolimus plus Somatostatin Analogues in Patients with Neuroendocrine Tumors.

Ge W, Zhou D, Zhu L, Song W, Wang W.

J Cancer. 2018 Dec 10;9(24):4783-4790. doi: 10.7150/jca.25908. eCollection 2018.

5.

Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs).

Vernieri C, Pusceddu S, Fucà G, Indelicato P, Centonze G, Castagnoli L, Ferrari E, Ajazi A, Pupa S, Casola S, Foiani M, Mazzaferro V, Pruneri G, Milione M, de Braud F.

Int J Cancer. 2019 Apr 1;144(7):1704-1712. doi: 10.1002/ijc.32042. Epub 2019 Jan 7.

PMID:
30520016
6.

Leptomeningeal metastases of a well-differentiated neuroendocrine tumour: a rare entity.

Versluis JM, Brandsma D, van den Berg JG, Tesselaar M.

BMJ Case Rep. 2018 Nov 3;2018. pii: bcr-2018-226557. doi: 10.1136/bcr-2018-226557.

PMID:
30391925
7.

A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors.

Chamberlain CE, German MS, Yang K, Wang J, VanBrocklin H, Regan M, Shokat KM, Ducker GS, Kim GE, Hann B, Donner DB, Warren RS, Venook AP, Bergsland EK, Lee D, Wang Y, Nakakura EK.

Mol Cancer Ther. 2018 Dec;17(12):2702-2709. doi: 10.1158/1535-7163.MCT-17-1204. Epub 2018 Sep 25.

PMID:
30254185
8.

Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.

Mujica-Mota R, Varley-Campbell J, Tikhonova I, Cooper C, Griffin E, Haasova M, Peters J, Lucherini S, Talens-Bou J, Long L, Sherriff D, Napier M, Ramage J, Hoyle M.

Health Technol Assess. 2018 Sep;22(49):1-326. doi: 10.3310/hta22490.

9.

Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence.

Lee L, Ito T, Jensen RT.

Expert Opin Pharmacother. 2018 Jun;19(8):909-928. doi: 10.1080/14656566.2018.1476492. Epub 2018 May 24.

10.

Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.

Pusceddu S, Vernieri C, Di Maio M, Marconcini R, Spada F, Massironi S, Ibrahim T, Brizzi MP, Campana D, Faggiano A, Giuffrida D, Rinzivillo M, Cingarlini S, Aroldi F, Antonuzzo L, Berardi R, Catena L, De Divitiis C, Ermacora P, Perfetti V, Fontana A, Razzore P, Carnaghi C, Davì MV, Cauchi C, Duro M, Ricci S, Fazio N, Cavalcoli F, Bongiovanni A, La Salvia A, Brighi N, Colao A, Puliafito I, Panzuto F, Ortolani S, Zaniboni A, Di Costanzo F, Torniai M, Bajetta E, Tafuto S, Garattini SK, Femia D, Prinzi N, Concas L, Lo Russo G, Milione M, Giacomelli L, Buzzoni R, Delle Fave G, Mazzaferro V, de Braud F.

Gastroenterology. 2018 Aug;155(2):479-489.e7. doi: 10.1053/j.gastro.2018.04.010. Epub 2018 Apr 13.

PMID:
29655834
11.

The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study.

Faggiano A, Modica R, Severino R, Camera L, Fonti R, Del Prete M, Chiofalo MG, Aria M, Ferolla P, Vitale G, Pezzullo L, Colao A.

Endocrine. 2018 Oct;62(1):46-56. doi: 10.1007/s12020-018-1583-7. Epub 2018 Mar 23.

PMID:
29572709
12.

Efficacy and safety of everolimus treatment in a hemodialysis patient with metastatic atypical bronchial carcinoid: case report and literature review.

Brizzi MP, La Salvia A, Tampellini M, Sonetto C, Volante M, Scagliotti GV.

BMC Cancer. 2018 Mar 20;18(1):311. doi: 10.1186/s12885-018-4205-0. Review.

13.

An Advanced Well-differentiated Pancreatic Neuroendocrine Carcinoma (NET-G3) Associated with Von Hippel-Lindau Disease.

Miki M, Kawabe K, Igarashi H, Abe T, Ohishi Y, Hashimoto R, Karashima T, Yamasaki I, Inoue K, Ito T, Ogawa Y.

Intern Med. 2018 Jul 15;57(14):2007-2011. doi: 10.2169/internalmedicine.0416-17. Epub 2018 Feb 28.

14.

Bone marrow edema associated with everolimus.

McDevitt RL, Quinlan C, Hersberger K, Sahai V.

Am J Health Syst Pharm. 2018 Jan 1;75(1):e23-e27. doi: 10.2146/ajhp170269.

PMID:
29273609
15.

Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors.

Salazar R, Garcia-Carbonero R, Libutti SK, Hendifar AE, Custodio A, Guimbaud R, Lombard-Bohas C, Ricci S, Klümpen HJ, Capdevila J, Reed N, Walenkamp A, Grande E, Safina S, Meyer T, Kong O, Salomon H, Tavorath R, Yao JC.

Oncologist. 2018 Jul;23(7):766-e90. doi: 10.1634/theoncologist.2017-0144. Epub 2017 Dec 14.

16.

Update in the Therapy of Advanced Neuroendocrine Tumors.

Uri I, Avniel-Polak S, Gross DJ, Grozinsky-Glasberg S.

Curr Treat Options Oncol. 2017 Nov 16;18(12):72. doi: 10.1007/s11864-017-0514-9. Review.

PMID:
29143892
17.

Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial.

Ferolla P, Brizzi MP, Meyer T, Mansoor W, Mazieres J, Do Cao C, Léna H, Berruti A, Damiano V, Buikhuisen W, Grønbæk H, Lombard-Bohas C, Grohé C, Minotti V, Tiseo M, De Castro J, Reed N, Gislimberti G, Singh N, Stankovic M, Öberg K, Baudin E.

Lancet Oncol. 2017 Dec;18(12):1652-1664. doi: 10.1016/S1470-2045(17)30681-2. Epub 2017 Oct 23.

PMID:
29074099
18.

Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis.

Fazio N, Buzzoni R, Delle Fave G, Tesselaar ME, Wolin E, Van Cutsem E, Tomassetti P, Strosberg J, Voi M, Bubuteishvili-Pacaud L, Ridolfi A, Herbst F, Tomasek J, Singh S, Pavel M, Kulke MH, Valle JW, Yao JC.

Cancer Sci. 2018 Jan;109(1):174-181. doi: 10.1111/cas.13427. Epub 2017 Nov 9.

19.

NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab ± everolimus for metastatic melanoma.

McWilliams RR, Allred JB, Slostad JA, Katipamula R, Dronca RS, Rumilla KM, Erickson LA, Bryce AH, Joseph RW, Kottschade LA, King DM, Leitch JM, Markovic SN.

Cancer. 2018 Feb 1;124(3):537-545. doi: 10.1002/cncr.31072. Epub 2017 Oct 17.

20.

Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea.

Lee KJ, Cho JH, Lee SH, Song SY, Lee KH, Jeong S, Ryu JK, Woo SM, Bang S, Lee JK, Lee TH, Paik WH, Kim YT, Lee WJ.

Cancer Chemother Pharmacol. 2017 Oct;80(4):799-805. doi: 10.1007/s00280-017-3421-7. Epub 2017 Sep 7.

PMID:
28884280

Supplemental Content

Loading ...
Support Center